S&P 500
7,516.60
+0.45%
Dow Jones
52,923.60
+0.01%
Nasdaq 100
29,706.80
+1.19%
Russell 2000
3,007.21
+0.49%
FTSE 100
10,654.20
-0.33%
Nikkei 225
69,824.80
+2.22%
Guardant Health

Guardant Health (GH) Q3 2025 Earnings

Reported Oct 29, 2025 at 4:07 PM ET · SEC Source

Q3 25 EPS

$-0.39

BEAT +20.33%

Est. $-0.49

Q3 25 Revenue

$265.2M

BEAT +11.87%

Est. $237.1M

vs S&P Since Q3 25

+85.1%

BEATING MARKET

GH +94.6% vs S&P +9.6%

Market Reaction

Did GH Beat Earnings? Q3 2025 Results

Guardant Health posted a notably strong third quarter, with revenue climbing 38.5% year-over-year to $265.20 million and a loss per share of $0.39, both well ahead of Wall Street expectations; analysts had modeled $237.06 million in revenue and a $0.… Read more Guardant Health posted a notably strong third quarter, with revenue climbing 38.5% year-over-year to $265.20 million and a loss per share of $0.39, both well ahead of Wall Street expectations; analysts had modeled $237.06 million in revenue and a $0.49 loss per share, translating to beats of 11.87% and 20.33%, respectively. The primary engine behind the outperformance was broad commercial momentum across all business lines, with oncology revenue reaching $184.40 million on 40% test volume growth and screening revenue surging to $24.11 million from just $1.00 million a year ago, driven by roughly 24,000 Shield colorectal cancer screening tests. Margin discipline added to the positive picture, as GAAP gross margin improved to 65% from 61% a year earlier. Looking ahead, management raised full-year 2025 revenue guidance to $965 to $970 million, implying approximately 31% growth, while lifting screening revenue guidance to $71 to $73 million; the company's expanding clinical data presence, including upcoming presentations at ESMO 2025, reinforces the scientific foundation underpinning that confidence.

Key Takeaways

  • • Oncology test volume grew 40% year-over-year with fifth consecutive quarter of accelerating Guardant360 Liquid volume growth
  • • Shield screening test ramp driving Screening revenue to $24.1 million from $1.0 million a year ago
  • • Biopharma & Data revenue growth driven by achievement of certain milestones under service agreements
  • • Non-GAAP gross margin improved to 66% from 63% year-over-year
24/7 Wall St

GH YoY Financials

Q3 2025 vs Q3 2024, source: SEC Filings

24/7 Wall St

GH Revenue by Segment

With YoY comparisons, source: SEC Filings

Q2 25 Q1 26

“This was an exceptional quarter for Guardant with broad-based growth across our business. Oncology volumes grew 40% year-over-year, driven by very strong performance across all products, including the fifth consecutive quarter of accelerating Guardant360 Liquid volume growth. Notably, this quarter we crossed over $1 billion in annualized revenue. This sets us up well to deliver on the long-term plan we presented at our Investor Day last month.”

— Helmy Eltoukhy, Q3 2025 Earnings Press Release

Back to GH Stock Page